Skip to Content
Merck
All Photos(1)

Documents

MAB858-1

Sigma-Aldrich

Anti-RSV Antibody, fusion protein, all type A, B strains, clone 133-1H

ascites fluid, clone 133-1H, from mouse

Synonym(s):

RSV

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

ascites fluid

antibody product type

primary antibodies

clone

133-1H, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
immunofluorescence: suitable

isotype

IgG2a

shipped in

wet ice

General description

RSV is a labile paramyxovirus that produces a characteristic fusion of human cells in tissue culture--the syncytial effect. Two subtypes, A and B, have been identified. Subtype B are characterized as the asymptomatic strains of the virus. The more severe clinical illnesses involve Subtype A strains.

Specificity

Directed against the 47-49 kDa Fusion Protein of RSV. Antibody MAB858-1 recognizes both A and B RSV strains.

Immunogen

A2
Epitope: all type A & B strains

Application

ELISA at 1:800+

Indirect Immunofluorescence at 1:100-200+ (fresh frozen tissue sections)

Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
This Anti-RSV Antibody, fusion protein, all type A, B strains, clone 133-1H is validated for use in ELISA, IF for the detection of Respiratory Syncytial Virus.

Physical form

Ascites fluid with 0.1% sodium azide as a preservative.
Unpurified

Storage and Stability

Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Analysis Note

Control
RSV Control Slides, Catalogue Number 5012-5

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

nwg

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E K Park et al.
Molecules and cells, 12(1), 50-56 (2001-09-20)
Respiratory syncytial virus (RSV) is one of the principal agents of bronchiolitis and pneumonia in young children. Thus, there is a strong need to make a safe and effective vaccine against the RSV infection. DNA immunization is very effective at
Wy Ching Ng et al.
Journal of virology, 90(1), 206-221 (2015-10-16)
It is well established that influenza A virus (IAV) attachment to and infection of epithelial cells is dependent on sialic acid (SIA) at the cell surface, although the specific receptors that mediate IAV entry have not been defined and multiple
Bahar Ahani et al.
Nature communications, 14(1), 4347-4347 (2023-07-20)
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV season. In this
Giulia Campanini et al.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 39(2), 119-124 (2007-04-25)
Human respiratory syncytial virus (hRSV) detection in nasopharyngeal aspirates (NPAs) from infants with acute respiratory tract infection (ARTI) does not prove the hRSV etiology of the current ARTI episode. HRSV RNA quantification may help in affording this issue. hRSV was
Bert Schepens et al.
EMBO molecular medicine, 6(11), 1436-1454 (2014-10-10)
Infections with human respiratory syncytial virus (HRSV) occur globally in all age groups and can have devastating consequences in young infants. We demonstrate that a vaccine based on the extracellular domain (SHe) of the small hydrophobic (SH) protein of HRSV

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service